Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,009 JPY | +0.20% | -1.37% | -19.41% |
May. 10 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
Mar. 18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an expected P/E ratio at 58.88 and 33.15 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.41% | 777M | - | ||
+52.52% | 59.28B | B- | ||
+41.87% | 40.94B | A | ||
-6.23% | 40.17B | B | ||
-5.56% | 28.69B | C | ||
+10.57% | 26.63B | B- | ||
-22.84% | 18.89B | B | ||
+30.34% | 12.46B | C+ | ||
+1.15% | 12.42B | B+ | ||
+25.21% | 12.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4974 Stock
- Ratings Takara Bio Inc.